1.60
-0.04(-2.44%)
Currency In EUR
Sector
Healthcare
Industry
Medical - Pharmaceuticals
Employees
14
First IPO Date
April 23, 2015
| Name | Title | Pay | Year Born |
| Dr. Frank T. Weber M.D. | Chief Executive Officer, Chief Medical Officer & Executive Director | 342,000 | 1960 |
| Dr. Konrad Glund | Co-Founder & Advisor | 222,113 | 1953 |
| Ms. Anne Doering C.F.A. | Chief Financial Officer & Executive Director | 303,000 | 1973 |
| Dr. Hendrik Liebers | Advisor | 319,196 | 1971 |
| Dr. Michael Schaeffer Ph.D. | Chief Business Officer & Executive Director | 352,000 | 1969 |
| Dr. Julia Neugebauer Ph.D. | Chief Operating Officer & Executive Board Member | 0 | N/A |
| Dr. Manuela Bader | Director of Investor Relations & Communications | 0 | N/A |
Vivoryon Therapeutics N.V., a clinical stage biopharmaceutical company, engages in the research and development of therapeutic products for the treatment of Alzheimer's disease. Its pipeline products target toxic pyroglutamate-Abeta (pGlu-Abeta), which inhibits the production of pGlu-Abeta. The company's lead product candidate is PQ912, a small molecule QC inhibitor that has completed Phase IIb clinical trials for use in the treatment of Alzheimer's disease; and for the treatment of cancer. Its preclinical development product is PQ1565, a small molecule glutaminyl-peptide cyclotransferase-like inhibitor for the treatment of cancer. In addition, the company is developing a monoclonal antibody targeting pGlu-Abeta to enhance its clearance. Vivoryon Therapeutics N.V. has a research collaboration agreement with University Medical Center Schleswig-Holstein to discover and develop therapeutics in cancer immunotherapy; collaboration agreement with Nordic Bioscience for the clinical development of PQ912 for Alzheimer's disease; and research collaboration with the Fraunhofer Institute for cell therapy and immunology, as well as a strategic regional licensing partnership with Simcere Pharmaceutical Group Ltd. to develop and commercialize medicines targeting the neurotoxic amyloid species N3pE (pGlu-Abeta) to treat Alzheimer's disease. Vivoryon Therapeutics N.V. was founded in 1997 and is headquartered in Halle, Germany.
